PRL-T2 10 MG

PRL-T2 is Peptiva Research Labs' house designation for a synthetic dual receptor-agonist peptide in the tirzepatide research class, engineered to co-activate the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. As a dual incretin agonist of these class B G-protein-coupled receptors, it serves as a reference compound for studying combined incretin signaling and its downstream metabolic effects. In the laboratory, researchers study PRL-T2 in receptor-binding and reporter assays, transfected cell systems, and preclinical models to characterize GIP and GLP-1 receptor engagement, cyclic-AMP and beta-arrestin signaling, and gene-expression changes relevant to glucose regulation. In-vitro work also compares the relative contribution of each receptor arm to overall signaling output and examines insulin-secretion pathways in pancreatic islet cell models. These studies are exploratory and mechanistic, with no human, veterinary, or clinical application. Peptiva Research Labs supplies it as a research-grade reference compound, HPLC-verified with a COA available. For Research Use Only, not for human or veterinary use.

Read the research guide: PRL-S1 (Semaglutide-Class GLP-1 Agonist): Research Overview →

Loading full product details…